Pravastatin Actavis

País: Nueva Zelanda

Idioma: inglés

Fuente: Medsafe (Medicines Safety Authority)

Ingredientes activos:

Pravastatin sodium 20mg;  

Disponible desde:

Teva Pharma (New Zealand) Limited

Designación común internacional (DCI):

Pravastatin sodium 20 mg

Dosis:

20 mg

formulario farmacéutico:

Tablet

Composición:

Active: Pravastatin sodium 20mg   Excipient: Croscarmellose sodium Iron oxide yellow Lactose monohydrate Light magnesium oxide Magnesium stearate Microcelac 100 Povidone

tipo de receta:

Prescription

Fabricado por:

Biocon Limited

indicaciones terapéuticas:

In hypercholesterolemic patients without clinically evident coronary heart disease, Pravastatin Actavis is indicated as an adjunct to diet to reduce the risk of fatal and non-fatal myocardial infarction, need for myocardial revascularisation procedures, and to improve survival by reducing cardiovascular deaths. Pravastatin Actavis is indicated for the reduction of elevated total and LDL-cholesterol levels in patients with primary hypercholesterolaemia when the response to diet and other nonpharmacological measures alone have been inadequate. Pravastatin Actavis is indicated as an adjunct to diet to slow the progressive course of atherosclerosis and reduce the incidence of clinical cardiovascular events in hypercholesterolaemic men under 75 years of age with coronary artery disease.

Resumen del producto:

Package - Contents - Shelf Life: Blister pack, Alu-Alu blister pack with cardboard carton secondary packaging - 30 tablets - 36 months from date of manufacture stored at or below 25°C protect from light and moisture

Fecha de autorización:

2014-01-20